The FDA has expanded the indication for lenalidomide (Revlimid, Celgene) to include use for patients with multiple myeloma as maintenance therapy following autologous hematopoietic stem cell transplant (auto-HSCT).
The expanded indication makes lenalidomide the first and only treatment to receive FDA approval for maintenance use following auto-HSCT.